YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided earnings guidance for the six months ended June 30, 2021. For the period, the Group is expects to record a net loss attributable to the parent company ranging from approximately RMB 494 million to approximately RMB 556 million as compared to the net profit attributable to the parent company of approximately RMB 618 million for the six months ended 30 June 2020, and a net loss attributable to the parent company ranging from approximately RMB 313 million to approximately RMB383 million for the six months ended June 30, 2021 as compared to the net profit attributable to the parent company of approximately RMB 696 million for the six months ended 30 June 202.